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To determine if proton magnetic resonance spectroscopy (1H-MRS) detect differences in dementia status in
adults with Down syndrome (DS), we used 1H-MRS to measure neuronal and glial metabolites in the posterior
cingulate cortex in 22 adults with DS and in 15 age- and gender-matched healthy controls. We evaluated associ-
ations between 1H-MRS results and cognition among DS participants. Neuronal biomarkers, including N-
acetylaspartate (NAA) and glutamate-glutamine complex (Glx), were significantly lower in DS patients with
Alzheimer's should probably be changed to Alzheimer (without ' or s) through ms as per the new naming stan-
dard disease (DSAD) when compared to non-demented DS (DS) and healthy controls (CTL). Neuronal bio-
markers therefore appear to reflect dementia status in DS. In contrast, all DS participants had significantly
higher myo-inositol (MI), a putative glial biomarker, compared to CTL. Our data indicate that there may be an
overall higher glial inflammatory component in DS compared to CTL prior to and possibly independent of devel-
oping dementia. When computing the NAA to MI ratio, we found that presence or absence of dementia could be
distinguished inDS. NAA, Glx, andNAA/MI in all DS participants were correlatedwith scores from the Brief Praxis
Test and the Severe Impairment Battery. 1H-MRSmay be a useful diagnostic tool in future longitudinal studies to
measure AD progression in personswith DS. In particular, NAA and theNAA/MI ratio is sensitive to the functional
status of adults with DS, including prior to dementia.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Down syndrome (DS) is a developmental disorder involving triplica-
tion of chromosome 21 and is one of the most common causes of intel-
lectual disability of known genetic etiology. Memory processes are
affected early in the course of aging in DS, and nearly all adults with
DS show sufficient neuropathology for a diagnosis of Alzheimer' disease
(AD) by their fifth decade of life (Mann and Esiri, 1989; Wisniewski et
al., 1985). Interestingly, despite the presence of AD neuropathology,
typically by age 40 years, dementia may not be observed until almost
a decade later (Zigman, 2013). Neuronal loss (Sadowski et al., 1999), re-
duced neurotransmitters (Schliebs and Arendt, 2011), and increased
neuroinflammation (Wilcock and Griffin, 2013; Wilcock et al., 2015a)
may play important roles in the development of dementia and
compromising cognition in DS. To identify biomarkers and critical
pathological cascades associated with dementia and develop novel inter-
ventions to slow disease progression, it is critical to develop diagnostic
strategies that enable early detection of the underlying neurobiological
changes in DS.
Protonmagnetic resonance spectroscopy (1H-MRS) has beenwidely
used to characterize neurochemical brain health and disease. In partic-
ular, the neuronal markers of N-acetylaspartate (NAA) and glutamate-
glutamine complex (Glx), and glial marker of myo-inositol (MI), corre-
spond to disease severity and often correlate well with clinical variables
in aging and AD (Parnetti et al., 1997; Lin and Rothman, 2014). Specifi-
cally, neuronal loss or injury can be indicated by lower than normal
levels of NAA and Glx, while neuroinflammation with activated astro-
cytes and microglia in brain disorders are associated with elevated MI
(Chang et al., 2013). To further distinguish the neuronal-glial interplay
the ratio of NAA to MI has been used for studies of sporadic AD and
has been useful for distinguishing nondemented fromdemented people
(example - Fig. 5 in (Lin et al., 2005)).
In DS, decreased NAA and increased MI have been observed in the
hippocampus of adults by MRS (Beacher et al., 2005; Lamar et al.,
2011) and in an early report of one individual with DS in the posterior
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parietal cortex (PCC) (Shonk et al., 1995). Interestingly, in a larger study
using MRS in people with DS with and without dementia, hippocampal
measures of Glx did not distinguish these two groups, and neither was
different from controls (Tan et al., 2014).In this study, we hypothesized
that signatures of neuronal health would be reduced, and those of in-
flammation increased in DS as a function of cognitive status particularly
in the PCC as it is a region where hypometabolism is observed in adults
with DS (Haier et al., 2003). Our long-term goal is to develop in vivo 1H-
MRS criteria for future clinical settings that enable early identification of
neurochemical differences, prediction of dementia development, and
consequently treatment efficacy, in adults with DS. We measured
brain metabolites using 1H-MRS and correlated them with cognitive
scores in adults with DS who are enrolled in a longitudinal study of
aging and dementia at the University of Kentucky.
2. Materials and methods
2.1. Participants
MRS measures were collected from the baseline visit of an ongoing
longitudinal study of adult DS evaluating decline in cognitive function-
ing and neural integrity as predictors of the development of dementia
(Powell et al., 2014). We recruited participants older than 35 years
through local DS support groups and residential facilities in Kentucky
and southern Ohio from 2010 to 2014. We excluded participants if
they had active and unstable medical conditions (e.g., cardiovascular
complications). Because thyroid dysfunction is common in individuals
with DS, we included these participants if their thyroid dysfunction
was medically controlled. The study cohort included 22 adults with DS
(Table 1).We also recruited 15 age- and gender-matched (by frequency
matching) non-DS control participants (CTL). CTL reported no history of
significant neurologic, cardiovascular, or psychiatric disorders. All par-
ticipants completed informed written consent or assent with guardian
consent. The study and research procedures were approved by the Uni-
versity of Kentucky Institutional Review Board.
2.2. Neurocognitive and behavioral measures
Expert consensus review of each participantwithDS determined de-
mentia diagnosis. Briefly, two neurologists and two neuropsychologists
applied NINCDS-ADRDA criteria for dementia (McKhann et al., 1984)
and reviewed all data frommedical history, medical and neurologic ex-
aminations, laboratory tests, structural imaging, mental status mea-
sures, and informant report of any changes in functional status and
activities of daily living. The purpose of the consensus conference is to
reach a single diagnosis through review of each participant's informa-
tion. Therefore, clinical ratings reflect a group decision among the 5 cli-
nicians. As for informant-based rating scales, each individual's primary
care provider completes the behavioral assessments (e.g., affect, Activi-
ties of Daily Living (ADL)). The care provider, identified as the
participant's guardian or person with daily contact if in a group or insti-
tutionalized setting (at least 8 h per week) is interviewed and remains
the primary informant at each scheduled study visit.
Dementia duration is based on the primary caregiver's report of the
age at onset of cognitive and ADL changes (subtracted from the age at
which the scan is obtained). Hence, persons recruited into the study
with dementia (verified in clinical consensus) have a longer duration
than participants who develop dementia after study enrollment
(shorter duration and greater precision of onset age). In addition,
some participants enroll in the study given caregiver concerns about
cognitive and ADL change. This results in a shorter duration value.
We obtained Dementia Questionnaire for Persons with Mental Re-
tardation (DMR) ratings from informants for each participant with DS
in addition to the objective mental status measures for diagnostic con-
firmation (Evenhuis, 1996). The DMR was developed in the 1990s by
Evenhuis and colleagues (Evenhuis, 1992) as a standardized screening Ta
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tool for dementia using caregiver report. It consists of eight subscales
that are combined into a total score and also yields subscores for cogni-
tion and social functioning. Each item is rated on the degree of deficit
(0 = none, 1 = moderate, 3 = severe) such that increasing scores re-
flect a greater degree of disability (0–104 for the total DMR).
Further, we derived premorbid levels of functioning from individual
case files of existing academic and psychological test records, medical
records, aswell as familymember interviews. Based on this information
participants were categorized as low, medium, and high functioning
based upon their level of intellectual disability (Lott, 2011). Premorbid
level of functioning in the current sample included 13 with mild ID
and 9 with moderate ID. All participants with DS completed medical
and cognitive assessments.
The Brief Praxis Test (BPT) (Dalton and Fedor, 1997) and the Severe
Impairment Battery (SIB) (Panisset et al., 1994) were used as neuropsy-
chological outcomemeasures for the present study. Bothmeasures have
demonstrated usefulness in tracking progressive decline due to demen-
tia in DS (Lott et al., 2012). The SIB is a mental status scale that was spe-
cifically developed to track AD progression during more advanced
stages of dementia. The current SIB version consists of 51 items across
nine domains (social interaction, memory, orientation, language, atten-
tion, praxis, visuospatial, constructional abilities, and orientation to
name). The scale has a maximum score of 100, has been used in clinical
trials in DSAD (Lott, 1822; Prasher et al., 2002), and has shown good
test-retest and criterion validity when used in DS (Witts and Elders,
1998). The BPT is derived from the Dyspraxia Scale for Adults with
Down Syndrome (Dalton et al., 1999) and consists of 20 items that eval-
uate both gross and fine motor functions. This 80-point scale has dem-
onstrated good reliability and sensitivity to change in DS and DSAD
(Sano et al., 2005).
2.3. 1H-MRS data acquisition and analysis
1H-MRS measurements were obtained immediately following ac-
quisition of neurocognitive measures. Participants were scanned on a
3T TIM Siemens scanner at the Magnetic Resonance Imaging and Spec-
troscopy Center at the University of Kentucky. The single 1H-MRS voxel
of interest (VOI; 80 cm3) was defined a priori in the posterior cingulate
cortex as confirmed by MPRage to be consistent with reports by Ross
and colleagues (Lin et al., 2005)(PCC; Fig. 1). High-resolution, 3D ana-
tomic images were acquired using an MP-RAGE sequence [repetition
time (TR) = 1690 ms, echo time (TE) = 2.56 ms, flip angle (FA) =
12°, 1 mm isotropic voxels, 6:19 min]. The rationale for selecting this
brain region was two-fold (Mann and Esiri, 1989): to reduce the impact
of movement artifacts, which can be a concern with imaging people
with DS and (Wisniewski et al., 1985); to select a brain region that is
sensitive to mild cognitive impairment and AD in the general popula-
tion in previous MRS studies (Lin et al., 2005; Tumati et al., 2013). A
Stimulated Echo Acquisition Mode (STEAM) sequence was used with
repetition time (TR) of 1500 ms and echo time (TE) of 35 ms, flip
angle = 90°, 128 averages and 1024 points; automated local shimming
and water suppression (Simmons et al., 1998). The rationale for using
STEAM was to allow us to compare our current results with ongoing
studies of MRS in people without DS with mild cognitive impairment
and AD at our imaging center and previous publications (Tumati et al.,
2013; Murata et al., 1993).
1H-MRS spectra were processed and the concentrations of the me-
tabolites were derived using LCModel on a Linux operating system.
LCModel uses a linear combination of model spectra of metabolite solu-
tions in vitro to analyze the major resonances of in vivo spectra
(Provencher, 1993). For each spectra, a signal to noise ratio was calcu-
lated by LCModel and a cut off of greater than 6 was used (range was
6–17) and the full width half maximum estimate of linewidth averaged
55.7 ppm. Data points for which the LCMODEL provided a % standard
deviation (for the fit) of lower than 15% for Cre, MI, NAA/NAAG (range
was 3–15%) and lower than 20% for Glx peaks (range 10–20% except
for one DS participant at 30%) were included in the analysis. The auto-
matic advanced DESS sequence was used to shim the spectroscopy
voxel. Shimming and gradientQA is conducted on the scanner bimonth-
ly to ensure reproducibility. The metabolites that consistently reached
our signal to noise ratio and % standard deviation included Cr, MI, Glx
(combined Glu and Gln) and NAA with NAAG (the NAA resonance at
2 ppm contains both NAA and N-acetylaspartylglutamate (NAAG). We
report results here reflecting the combination of NAA andNAAG, though
we use the term of NAA for brevity. The concentration of all the 1H-MRS
metabolites was normalized to that of Cr as described in previous re-
ports (summarized in (Tumati et al., 2013)).
2.4. Statistics
Statistical analyses were performed using GraphPad Prism
(GraphPad, San Diego, CA, USA) and IBM SPSS Statistics (Version 22).
Mean differences inmetabolites, volunteer demographics and cognitive
test scores among the three groups (DS, DSAD, CTL) were evaluated
using one-way analysis of variance (ANOVA) with Tukey's Multiple
Comparisons (and nonparametric ANOVA; Kruskal-Wallis). In addition,
Pearson correlation coefficients were used to explore associations be-
tween metabolites and mental status. Values of p b 0.05 were consid-
ered significant.
Fig. 1. 1H magnetic resonance spectroscopy study design and spectra. A. The inset image illustrates the PCC region VOI used for MRS measures, on an MPRAGE image. The graphs are
examples of spectra of B. control (CTL), C. nondemented Down syndrome (DS) and D. Down syndrome with Alzheimer's dementia (DSAD) participants. Cho: choline; Cr: creatine; Glx:
glutamate-glutamine complex; MI: myo-inositol; NAA: N-acetylaspartate; ppm: parts per million.
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3. Results
3.1. Demographic characteristics and neurocognitive measure outcomes
Table 1 displays the demographics and group means on the BPT and
SIB for the DS groups. As expected, there were no significant age differ-
ences across the groups. Among the 22 adultswith DS, 5 females (but no
males) were identified with dementia due to Alzheimer's disease
(DSAD). To address possible confounding due to having only females
in the DSAD group, we compared metabolite levels in the control
group between males and females and observed no significant differ-
ences (data not shown). Similar results were obtained when comparing
males and females in the DS group. However, samples sizes in this study
preclude strong conclusions regarding gender differences as has been
reported in MRS studies in sporadic AD. DSAD participants had signifi-
cantly lower scores on the BPT (t = −3.32, p = 0.0036) and SIB
(t =−3.26, p= 0.0039) compared to DS participants without demen-
tia (referred to asDS). Levels of intellectual disability prior to a diagnosis
of dementia did not differ between the participants with DS and DSAD
(Fisher's exact test p = 0.45) as the sample reflected a 50%/50% split
of participants in the mild and moderate ranges overall and a 20%/30%
split for those persons diagnosed with dementia.
3.2. Differences in neuronal and glial biomarkers in the DS participants
Fig. 1 shows the representative spectra from each group. The DSAD
participants had reduced NAA and Glx but elevated MI compared to
the other two groups. NAA, at 2.0 ppm, is an amino acid derivative syn-
thesized in neurons and transported down axons. Therefore, it is an
almost 100%-specific marker of viable neurons, axons, and dendrites
(Lin et al., 2005). Glx, which lies between 2.1 and 2.4 ppm, is a mixture
of glutamate and glutamine, which is closely involved in excitatory/in-
hibitory neurotransmission and the mitochondrial redox system. As a
result, Glx provides a marker in MRS for neural integrity. MI, which res-
onates at 3.5 ppm, may represent glial activation (as an osmoylte that
maintains glial cell volumes) (Chang et al., 2013) as well as membrane
metabolism (Lamar et al., 2011). It is therefore used as a putative glial
biomarker.
The quantitative results shown in Fig. 2 further revealed the differ-
ences between DS, DSAD, and CTL groups. The neuronal biomarkers,
Glx (Fig. 2A; F2.34 = 4.225, p= 0.02) and NAA (Fig. 2B; F2.34 = 19.98,
p b 0.0001) were significantly lower in DSAD participants, but no differ-
ences were found between DS and CTL (p N 0.05). However, in the glial
biomarker, we found that MI in both DS and DSAD patients was signif-
icantly higher relative to CTL (Fig. 2C; F2.34 = 22.64; p b 0.0001), but
no difference was found between DS and DSAD (p N 0.05).
3.3. Neuronal-glial metabolism shifts in DS
The NAA/MI ratio distinguished CTL, DS, and DSAD groups by
ANOVA (F2.34 = 29.33; CTL vs. DS: p b 0.001; CTL vs. DSAD: p b 0.001;
DS vs. DSAD: p b 0.01; note: Kruskal-Wallis Test, statistic = 21.404;
p b 0.0001). CTL had the highest value (2.4 ± 0.4), followed by DS
(1.7 ± 0.3 ppm), and DSAD had the lowest value (1.1 ± 0.1 ppm)
(Fig. 2D). However, using a stepwise linear regression, using the NAA
value alone provides the best predictor for distinguishing demented vs
nondemented people with DS compared with the NAA/MI ratio (r2 =
0.608). In contrast, a similar regression analysis including all DS and
Fig. 2. Brain metabolite differences in DS and DSAD participants. (A) and (B) DSAD participants had significantly lower Glx and NAA compared to the other two groups; (C) Down
syndrome participants, whether demented or not, had significantly higher MI relative to the CTL; (D) CTL, DS and DSAD showed significantly different NAA/MI ratio. All the
metabolites were normalized to creatine. Glx: glutamate-glutamine complex; MI: myo-inositol; NAA: N-acetylaspartate. n.s. = non-significant. Bars represent SEM. Females are shown
as closed circles and males as open circles.
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control participants, the relationship changes and the ratio of NAA/MI is
a better predictor of dementia than NAA alone (r2 = 0.633).
Fig. 3 shows the relationship between NAA andMI among the three
groups. A combination of low NAA and high MI clearly separated DSAD
individuals from the other two groups, suggesting that NAA values
lower than 1.0 and MI values higher than 0.65 (i.e., NAA/MI b 1.54)
may be a key threshold for discriminating DS with AD from DS without
AD. Further, DS without dementia had overlapping NAA values with
CTL, but most were over 0.55 values for MI.
3.4. Brain metabolites and cognition associations
To test the hypothesis that reduced neuronal and increased glialme-
tabolites by MRS would be associated with poorer cognition in DS, we
used Pearson correlations unadjusted for multiple comparisons. One
person with DS who was demented could not complete the BPT task.
Fig. 4 shows individual test scores for participants in the study andhigh-
lights those with (open circles) and without dementia (closed circles).
We found that higher NAA values were associated with higher BPT
(Fig. 4A; r = 0.65, p = 0.002) and SIB (Fig. 4B; r = 0.60, p = 0.003)
scores; BPT was also positively correlated with Glx (Fig. 4C; r = 0.45,
p = 0.040) and NAA/MI (Fig. 4D; r = 0.50, p = 0.022). SIB scores
were positively correlated with NAA but not with Glx or the NAA/MI
ratio. Given that the presence/absence of dementia is confounded
with cognitive test scores, we also calculated correlations when only
the nondemented participants were included in the analysis. The corre-
lation between BPT and NAA remained significant (r = 0.485 p =
0.048) and the SIB correlation with NAA was marginally significant
(r = 0.456 p= 0.066). The correlations between BPT and Glx or NAA/
MI were not significant suggesting that people with dementia are pri-
marily responsible for driving the association between BPT and Glx or
NAA/MI.
4. Discussion
In the current study, we show data that suggest that 1H-MRS of the
posterior cingulate cortex could be a powerful tool to differentiate be-
tween aging and dementia inDS.We found that DS participants (includ-
ing those with and without dementia) had an overall higher MRS
marker of glial inflammation (MI) compared to the CTL group. These re-
sults indicate that people with DS, whether demented or not, had a
shifted neuron-glial metabolism (reduced NAA and increased MI); the
shift was more pronounced in the demented DS individuals than the
non-demented DS adults. Further, MI overlapped to some extent in
the DS and DSAD groups suggesting that either MI increases are already
present over the age of 35 years in DS and may be developmental or an
early aging event. Increased MI in younger adults with DS in the hippo-
campus has been reported suggesting this is a phenotype of DS (Beacher
et al., 2005). The NAA/MI ratio could be an index to predict the risk for
dementia in DS adults especially given that there was no overlap be-
tween the two groups in their NAA/MI ratios. Thus people with DS,
whether demented or not, may have neuroinflammatory processes ac-
tive after 35 years of age compared to non-DS healthy controls, andneu-
ronal function lossmay be the key factor associatedwith dementia inDS
participants. In addition, the DSAD participants also had a lower MRS
marker of neuronal integrity (NAA) than the DS and CTL participants.
The NAA/MI ratio further differentiated CTL, DS, and DSAD, with re-
duced levels in the demented group.
Last, we provide novel data showing a link between decreased NAA
in the PCC in DS that reflects cognitive functioning as reflected in BPT
and SIB scores in DSwith andwithout dementia. In addition, these find-
ings support prior reports showing that the PCC is involved in attention-
al control (Small et al., 2003) and focus (Leech and Sharp, 2014); PCC
has also been linked to constructional ability in early AD (Nobili et al.,
2005). The involvement of the PCC in cognition is evolving as new con-
cepts and its associations with the default mode network are being de-
scribed. For example, reports that are relevant to our current findings in
DS, PCC connectivity changes have been reported in Alzheimer's disease
(AD) aswell asMild Cognitive Impairment (MCI) alongwith association
withmemory performance (e.g. (Zhou et al., 2008)). Further, Leech et al.
(2011) and Leech and Sharp (2014) have developed a theoretical
framework, of the PCC as an ‘information processing hub’ given its con-
nectivity to heteromodal association cortex, limbic and paralimbic
structures, as well as cognitive functions such as working memory
(Leech and Sharp, 2014; Leech et al., 2011). If we apply Leech and
colleague's model of the PCC as an ‘Arousal, Balance, and Breadth of At-
tention’model to our presentfindings, the group differences seen on the
BPT and SIB reflect changes in PCC support of cognitive control and
memory retrieval as well as multitasking as evaluated by these
procedures.
The NAA-MI ratio has beenwidely considered as sensitive to disease
progression and treatment efficacy in AD (Lin et al., 2005). In particular,
the NAA/MI ratio discriminates reliably between AD subjects and nor-
mal individuals in the general population andprovides useful outcomes,
as an adjunct to structural MRI and other physiological imaging (Jones
andWaldman, 2004; Lin et al., 2012). To further distinguish the neuro-
nal-glial interplay among the three groups, we examined the ratio be-
tween NAA and MI as has been reported for sporadic AD (Lin et al.,
2005). We found similar results in adults with DS in the present study.
Compared to NAA or MI when used alone, the mean NAA/MI ratio was
statistically different in the CTL, DS and DSAD diagnostic groups. In par-
ticular, the individual variability of this ratio in the five demented DS
participants was low, suggesting that the NAA/MI ratio had a high sen-
sitivity to detect pathological and functional status among DS individ-
uals, even with a small sample size. Some caution is warranted
regarding the diagnostic use of the NAA/MI ratio based on our sample.
Despite 100% correct classification with this group of participants, con-
fidence intervals are broad based on the small sample and the variability
seen in the DS only group (Fig. 3). Thus there may be different cutoffs
generated across independent studies and it would be interesting to
combine results across studies to determinehow this cut off generalizes.
DecreasedNAAand increasedMI have also been observed in the hip-
pocampus of DS adults byMRS (Beacher et al., 2005; Lamar et al., 2011)
and in an early report of one individual with DS in the PCC (Shonk et al.,
1995). In people with DS with and without dementia, hippocampal
measures of Glx did not distinguish these two groups, and neither was
different from controls (Tan et al., 2014). In this study, we chose a priori
to do the measurements in PCC because PCC demonstrates early meta-
bolic deficits and astrocytic inflammation in AD (Leech and Sharp, 2014;
Minoshima et al., 1997) and may provide a more reliable set of mea-
sures as it is less sensitive to head movement.
The marked increases of MI in all of the DS participants indicated
that this group had higher glial inflammation compared to the healthy
controls, which might make them more susceptible to AD. Our results
Fig. 3. Plot of NAA/MI ratio as diagnostic criteria for DSAD. Significantly lower NAA and
relatively higher MI (i.e. the NAA/MI ratio) separates DSAD from DS and CTL. NAA and
MI were normalized to creatine.
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are consistent with previous reports of increased MI by MRS in the oc-
cipital and parietal cortex (Huang et al., 1999), and hippocampus
(Beacher et al., 2005) in nondemented adults with DS. Lamar et al.
(2011) also found that hippocampalMI byMRSwas higher in demented
adults with DS compared to those without dementia (Lamar et al.,
2011). In a description of one individual with DS, MRS of the PCC also
showed increased MI (Shonk and Ross, 1995). Further, MI levels in the
PCC are correlated with cognitive scores. It is interesting to note that
the MI cotransporter (SLC5A3) gene is on chromosome 21 and
overexpressed in DS (Berry et al., 1995) and further, that synaptojanin
1, which is also overexpressed in DS, leads to increased gliosis
(Herrera et al., 2009). Thus, higher MI levels in DS may reflect develop-
mental differences in DS, with a lesser involvement in AD pathogenesis
per se. Consistent with this interpretation are the relatively weak corre-
lations betweenMI and cognitive measures that reflect dementia in the
current study, aswell as a study in 3–15 year old childrenwithDS show-
ing similar decreased mI/Cr ratios (Smigielska-Kuzia et al., 2010).
We recognize that there may be a systematic difference in brain vol-
ume and composition between our demented and nondemented partic-
ipants. A recent study suggests that partial volume effects are important
when quantifyingMRS and that knowing the voxel composition of grey
and white matter as well as cerebrospinal fluid can reduce variability in
studies that include people with neurodegenerative diseases (Mato
Abad et al., 2014) Further, there is an age related decrease in cortical
thickness in the cingulate gyrus in nondemented adults with DS,
which is more rapid between 20–30 years of age (Romano et al.,
2016). This suggests that decreased NAA in our studymay reflect partial
volume effects and potentially be overestimated On the other hand, MI
increases, against a potential decrease in volume and thusmay be a con-
servative estimate. In the current study, there were delays in the time
between anatomical imaging and MRS to reduce the time participants
were required to be in the scanner, which can be a challenge for people
with DS. In ongoing studies, we are now ensuring that these two imag-
ing protocols are acquired together.
Brain metabolism is tightly coupled with cerebrovascular function
(Lin et al., 2010; Fox et al., 1988) and brain hypoperfusion in DS adults
(Gupta and Ratnam, 2011). It is interesting to note that people with
DS appear to be protected from some cerebrovascular risk factors in-
cluding being relatively free of atherosclerosis (Murdoch et al., 1977)
and less frequent hypertension (Draheim et al., 2010; Draheim et al.,
2002; Morrison et al., 1996).However, there is extensive cerebral amy-
loid angiopathy in DS brain (Belza and Urich, 1986; Ikeda et al., 1994)
and this may lead to microhemorrhages and strokes (Belza and Urich,
1986; Donahue et al., 1998; Jastrzebski et al., 2015). Not all studies re-
port strokes in the aging brains of people with DS (Ikeda et al., 1994;
Lai and Williams, 1989). In older adults with DS who were
nondemented, hyoperfusion is observed in the PCC (Haier et al.,
2003), the temporal and frontal cortices as well as the hippocampus
(Haier et al., 2008).It is important for future studies to investigate the
role of cerebrovascular dysfunction and the development of dementia
in DS using non-invasive, well-validated neuroimaging methods, in-
cluding cerebral blood flow and cerebral blood volume measurements
(Wilcock et al., 2015b).
5. Conclusions
In conclusion, we used 1H-MRS to identify metabolic deficits as sur-
rogate markers of dementia in adults with DS. Novel features of our
study include the systematic imaging of the posterior cingulate cortex
in a cohort of adults with DS, which is vulnerable to early AD
Fig. 4. Positive correlations between brainmetabolites and cognitive outcomemeasures in adults with Down syndrome. NAAwas positively correlatedwith (A) BPT and (B) SIB; BPT was
also positively correlated with (C) Glx and (D) NAA/MI ratio. All the metabolites were normalized to creatine. Open circles show the people who were demented and closed circles were
nondemented.
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neuropathology and the correlationwith cognitive test scores. Although
we assume that AD in DS is similar to sporadic AD, the current study
confirms this hypothesis with respect to MRS biomarkers in the poste-
rior cingulate. Caveats to our study include the small sample size of
adults with dementia with DS and the need for longitudinal measures.
In future it will be useful to the current data to establish a ROC that
can be tested in additional participants as they are recruited to the
study. We are currently following the described DS groups in a longitu-
dinal study of aging in DS. The current imaging criteria require replica-
tion in a second cohort but may have future clinical implications for
DS individuals, such as aiding early detection of risk for dementia, longi-
tudinal follow-up of metabolic changes, and evaluation of therapeutic
efficacy.
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